Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 90.85% is in line with its 5-year average of 89.33%, near the high end of its 5-year range (85.34%–91.88%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.50% above its 12-month average of 89.51%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 90.93%.
GROSS MARGIN
90.85%
GROSS MARGIN AVG TTM
89.51%
GROSS MARGIN AVG 3Y
89.55%
GROSS MARGIN AVG 5Y
89.33%
GROSS MARGIN AVG 10Y
64.17%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.50%
CURRENT VS 3Y AVG
+1.45%
CURRENT VS 5Y AVG
+1.71%
CURRENT VS 10Y AVG
+41.58%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+119.55%
vs the sector median at left
UroGen Pharma Ltd.
Market Cap
$2.02B
Gross Margin
90.85%
TTM Avg
89.51%
3Y Avg
89.55%
5Y Avg
89.33%
Market Cap
$2.02B
Gross Margin
97.82%
TTM Avg
97.53%
3Y Avg
97.80%
5Y Avg
96.20%
Market Cap
$2.01B
Gross Margin
90.36%
TTM Avg
88.22%
3Y Avg
91.04%
5Y Avg
93.63%
Market Cap
$1.99B
Gross Margin
17.11%
TTM Avg
17.72%
3Y Avg
20.44%
5Y Avg
20.08%
Market Cap
$2.05B
Gross Margin
74.56%
TTM Avg
73.48%
3Y Avg
70.60%
5Y Avg
69.69%
Market Cap
$2.06B
Gross Margin
99.55%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
-349.27%
Market Cap
$1.98B
Gross Margin
86.13%
TTM Avg
85.03%
3Y Avg
84.60%
5Y Avg
84.81%
Market Cap
$2.07B
Gross Margin
100.00%
TTM Avg
-1064.88%
3Y Avg
-1783.56%
5Y Avg
-1442.31%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.02B | 90.85% | 89.51% | 89.55% | 89.33% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | 97.82% | 97.53% | 97.80% | 96.20% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.01B | 90.36% | 88.22% | 91.04% | 93.63% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 24.57% | 22.67% | 22.13% | 21.88% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.99B | 17.11% | 17.72% | 20.44% | 20.08% |
| Vericel Corporation (VCEL)vs › | $2.05B | 74.56% | 73.48% | 70.60% | 69.69% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | 99.55% | 100.00% | 100.00% | -349.27% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 86.13% | 85.03% | 84.60% | 84.81% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | 100.00% | -1064.88% | -1783.56% | -1442.31% |
| Alvotech (ALVO)vs › | $2.07B | 60.45% | 60.99% | 17.21% | 44.81% |
Gross Margin
90.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 90.93% |
| 2026-03-31 | 91.88% |
| 2025-12-31 | 91.31% |
| 2025-09-30 | 88.07% |
| 2025-06-30 | 85.34% |
| 2025-03-31 | 88.50% |
| 2024-12-31 | 89.94% |
| 2024-09-30 | 90.27% |
| 2024-06-30 | 89.80% |
| 2024-03-31 | 90.80% |
| 2023-12-31 | 90.28% |
| 2023-09-30 | 88.65% |
| 2023-06-30 | 88.44% |
| 2023-03-31 | 86.83% |
| 2022-12-31 | 87.49% |
| 2022-09-30 | 87.45% |
| 2022-06-30 | 88.88% |
| 2022-03-31 | 88.76% |
| 2021-12-31 | 90.18% |
| 2021-09-30 | 89.04% |
| 2021-06-30 | 89.05% |
| 2021-03-31 | 88.02% |
| 2020-12-31 | 91.82% |
| 2020-09-30 | 91.07% |
| 2020-06-30 | 87.10% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | -272.79% |
| 2018-06-30 | 12.64% |
| 2018-03-31 | 10.60% |
| 2017-12-31 | 12.23% |
| 2017-09-30 | 96.22% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 5.26% |
| 2016-12-31 | 99.84% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
